Skip to main content
. 2023 Oct 17;10:1254232. doi: 10.3389/fmolb.2023.1254232

FIGURE 9.

FIGURE 9

Variations in IC50 values of different immunotherapy drugs were examined based on risk scores: (A) AZ960, (B) BMS-345541, (C) BMS-536924, (D) Epirubicin, (E) IGF1R_3801, (F) Luminespib, (G) OTX015, (H) Sabutoclax, and (I) Ulixertinib.